How to Evaluate a Healthcare Startup Advisor Before They Join Your Board or Cap Table

Adding an advisor to your healthcare startup costs more than the equity or fee on the table. A board seat carries real governance weight, and even an informal advisory relationship shapes the advice you hear in the room during decisions that are hard to reverse. In a sector where a wrong regulatory assumption or a missed reimbursement detail can cost a year, the advisor you pick matters as much as the round you're raising. Here's a framework for evaluating one before you commit.

Why This Decision Carries More Weight in Healthcare

Generic startup advice doesn't transfer cleanly to healthcare. An advisor who's sharp on go-to-market for a consumer app may have nothing useful to say about clinical trial design, FDA pathway selection, or how a reimbursement decision reshapes a business model overnight. And because healthcare timelines run longer than almost any other sector — years between a technical milestone and a commercial one — a bad advisor fit doesn't resolve itself quickly. You're often stuck with the seat, and the dynamic, for longer than you'd like.

The Three Types of Healthcare Startup Advisors

Not every advisor solves the same problem, and conflating them is how founders end up with three people who all do the same thing — or worse, three real gaps nobody's covering. Broadly, healthcare startup advisors fall into three categories.

Clinical and regulatory advisors — physicians, former regulatory officials, reimbursement specialists — tell you whether your regulatory pathway assumption is real and what a payer will actually pay for. This is the advisor whose absence you don't notice until a regulatory surprise costs you a year.

Capital and network advisors bring access more than expertise: to investors, to a physician community like Healthcare Shares, to other founders who've been through your specific fundraising stage. Their job is opening doors you can't open yourself.

Founder-support advisors help with the part almost nobody puts on a board deck: staying psychologically steady enough to make good decisions through years of regulatory uncertainty, team strain, and the specific pressure of being the person everyone else looks to for confidence you don't always have. This is the category most healthcare boards are missing entirely — and it's often the gap I see founders working through in founder consulting conversations by year three.

Most healthy healthcare startups need at least one of the first two. Few think to look for the third until they're already in a rough stretch. Knowing which gap you're actually trying to fill changes who you should be evaluating in the first place.

Eight Questions to Ask Before They Join Your Board or Cap Table

What Advisor Equity Actually Looks Like, By Stage

Advisor equity varies meaningfully by stage, and it's worth knowing the rough range before you're negotiating in the moment rather than after.

Pre-seed / concept stage: 0.25%–1%, often with a shorter vesting period (12–18 months), since the advisor's specific value — an intro, a regulatory sanity check — tends to front-load early.

Seed stage: 0.1%–0.5%, typically vesting over 24 months, reflecting a larger existing cap table and more established company value.

Series A and beyond: 0.05%–0.25%, occasionally structured as a small cash retainer instead of or alongside equity, since dilution math gets less forgiving as the company matures.

These are norms, not rules — an advisor who's also investing capital, taking a board seat, or bringing a genuinely rare relationship can reasonably sit above these ranges. The number matters less than whether it's tied to a real vesting schedule, rather than a fully-vested grant handed out on day one with no ongoing obligation attached.

Red Flags Worth Walking Away From

A 90-Day Way to Evaluate Someone Before You Commit

If you have the luxury of time, evaluating an advisor over a defined period beats deciding after a single good conversation.

Days 1–30 — informal conversations. No commitment on either side, just enough exposure to see how they think about a problem you're actually facing, not a hypothetical one.

Days 31–60 — a small, specific ask. Have them weigh in on one real decision — a regulatory question, an intro they've offered to make, feedback on a pitch. This is where you find out whether they follow through, not just whether they talk well.

Days 61–90 — a formal proposal, once you've actually seen them work under real conditions rather than just heard them describe how they'd work. This is also the point to request founder references, now that you have specific moments to ask those references about.

Most bad advisor relationships trace back to skipping straight from a good first conversation to a signed agreement. Ninety days costs you little and tells you more than any reference call in isolation ever will.

What This Looks Like in Practice

If you're running this checklist, it's worth holding anyone — including me — to the same standard. My Healthcare page lays out my own board and investment record in the same terms this article asks you to look for: a board seat at Healthcare Shares, a physician-backed venture community; Lead Investor in Radix Motion, acquired by Red Light Holland Corp.; early investor in Circularis, acquired by Ginkgo Bioworks; and in Volumetric Biotechnologies, acquired by 3D Systems. If any of the eight questions above feel relevant to a decision you're making right now, that page is the place to start.